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HLA class II genes are strongly associated with susceptibility and
resistance to insulin-dependent diabetes mellitus (IDDM). The pres-
ent study reports the HLA-DRB1 genotyping of 41 IDDM patients and
99 healthy subjects from the Southeast of Brazil (Campinas region).
Both groups consisted of an ethnic mixture of Caucasian, African
Negro and Amerindian origin. HLA-DRB1*03 and *04 alleles were
found at significantly higher frequencies among IDDM patients com-
pared to the controls (DRB1*03: 48.8% vs 18.2%, P<0.005, RR =
4.27; DRB1*04: 43.9% vs 15.1%, P<0.008, RR = 4.37) and were
associated with a susceptibility to the disease. DRB1*03/*04 het-
erozygosity conferred a strong IDDM risk (RR = 5.44). In contrast, the
HLA-DRB1*11 allele frequency was lower among IDDM patients
(7.3% vs 26.3% in controls), but the difference was not significant.
These data agree with those described for other populations and allow
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(IDDM) is an autoimmune syndrome result-
ing from the destruction of pancreatic ß cells
by autoreactive T lymphocytes (1,2). The
development of the disease involves the in-
teraction of multiple genes and environmen-
tal factors (1,2). Several studies have indi-
cated a prominent role for major histocom-
patibility complex (MHC) genes on chromo-
some 6 in conferring susceptibility and resis-
tance to IDDM in a variety of human popula-
tions (3-5). In particular, the class II HLA
region that encodes molecules involved in
antigen presentation to CD4+ T cells repre-
sents the strongest genetic marker for the
disease (3-5). The association of IDDM with
the HLA-DR specificities DR3 and DR4 was
initially demonstrated by serological HLA
analysis (6-8). HLA genotyping has now
confirmed these data and has also facilitated
the identification, in Caucasians, of the two
most strongly predisposing haplotypes, the
DRB1*03-DQA1*0501-DQB1*0201, and
DRB1*04-DQA1*0301-DQB1*0302 (3).
The genetic basis of IDDM has been
poorly investigated in the Brazilian popula-
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tion. Only one report by Eizirik et al. (9) has
described the frequency of serologically de-
fined DR antigens in IDDM patients. The
Brazilian population is characterized by a
complex genetic background resulting from
the intermixing of Caucasians, Negroes and
Amerindians (10). The aim of the present
study was to determine the distribution of
HLA-DRB1* alleles in a mixed population
of IDDM patients from Southeastern Brazil.
Material and Methods
Subjects
Forty-one unrelated IDDM patients diag-
nosed according to the National Diabetes
Data Group criteria (11) and accompanied at
the Endocrinology Service of the University
Hospital of the State University of Campinas
(UNICAMP) were studied. The group con-
sisted of 26 women and 15 men. Mean age at
the time of IDDM diagnosis was 17.7 ± 7.9
years. All of the patients were residents of
Campinas and the surrounding region in the
State of São Paulo, and had a mixed genetic
background of European, African and Am-
erindian origin. Ninety-nine racially matched
healthy subjects from the same geographic
area were included as the control group. All
subjects gave informed consent to partici-
pate in the study, which was approved by the
Ethics Committee of the Hospital.
HLA genotyping
HLA-DRB1* genotyping was performed
using the polymerase chain reaction-se-
quence-specific oligonucleotide (PCR-SSO)
protocol recommended by the XII Interna-
tional Histocompatibility Workshop. Briefly,
DNA was obtained from peripheral leuco-
cytes by classic phenol/chloroform extrac-
tion. The amplification of exon 2 of the
HLA-DRB1 locus was performed by PCR
using aliquots of DNA (0.5 µg) in the pres-
ence of a forward primer spanning intron-4
(CCGGATCCTTCGTGTCCCCACAGCACG)
and a reverse primer spanning 88-94 bp (TC
GCCGCTGCACTGTGAA). Thirty cycles
were carried out with Taq DNA polymerase
in a Perkin-Elmer Cetus DNA thermal cy-
cler, as follows: 1 min at 95oC (denaturing),
1 min at 55oC (annealing) and 1 min at 72oC
(elongation). The resulting 292-bp fragment
was blotted onto nylon membranes and hy-
bridized overnight at 54oC with a set of 18
SSO probes, labeled with digoxigenin-11-
ddUTP (Boehringer Mannheim). The mem-
branes were then incubated with a Fab anti-
digoxigenin IgG (Boehringer Mannheim) and
detection was performed with a chemilumi-
nescence substrate (Lumigen PPD, Boehrin-
ger Mannheim). The dots were visualized
after a 10- to 20-min exposure to Kodak
XAR films at room temperature.
Statistical analysis
The distribution of HLA-DRB1* alleles
was compared between IDDM patients and
controls by the chi-square test with Yates
correction. Odds ratios were calculated ac-
cording to the formula of Woolf and, by
convention, expressed as relative risks (RR).
When one element was 0, the Haldane for-
mula was used to deduce the RR. The level
of significance was set at 0.05. The P value
was corrected by the Bonferoni inequality
method, by multiplying P by the number of
alleles compared.
Results
The HLA-DRB1* phenotype and allele
frequencies among IDDM patients and nor-
mal individuals are shown in Table 1 and
Table 2, respectively. HLA-DRB1*03 fre-
quency (Table 1) was significantly higher in
the IDDM than in the control group (48.8%
in IDDM, 18.2% in controls, RR = 4.27,
P<0.005). The HLA-DRB1*04 frequency
was also significantly higher in the IDDM
group (43.9% vs 15.1% in controls, RR =
367
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4.37, P<0.008). HLA-DRB1*03/*04 het-
erozygosity conferred a strong IDDM risk
(14.6% in patients vs 3.0% in controls, RR =
5.44).
Homozygosity for DRB1*03 and
DRB1*04 did not confer a higher risk than
having a single dose of these alleles (Table 2).
In contrast, the HLA-DRB1*11 frequency
was decreased in IDDM patients (7.3%) com-
pared with the control group (26.3%), but
the difference was not significant when the P
value was corrected by the number of DRB1
alleles tested (P<0.02 before correction). The
frequencies of the other HLA-DRB1* alle-
les were similar in both groups.
Discussion
Susceptibility and resistance to IDDM
are controlled, in part, by HLA class II genes
(3). In addition to the role of the encoded
molecules (particularly HLA-DQ) in the
immunopathogenesis of IDDM, these gene
products also serve as genetic markers that
are widely used to identify individuals with a
risk of developing IDDM (12,13).
Little is known about class II HLA genes
and IDDM in Brazilians. In the present study,
we used HLA genotyping to perform DRB1*
analysis in IDDM patients and normal indi-
viduals from Southeastern Brazil. There was
an increased frequency of HLA-DRB1*03
and *04 among IDDM patients compared to
the controls. These results are in agreement
with data obtained for other Caucasian, Afri-
can and Oriental groups (14-16). The strong
IDDM risk conferred by DRB1*03/*04 het-
erozygosity in the Brazilian IDDM group is
of the same order of magnitude as that ob-
served in Caucasian patients (14,16).
We found a tendency to a lower fre-
quency of HLA-DRB1*11 in IDDM patients
than in healthy individuals, although the dif-
ference was not significant after P correc-
tion. Other studies have previously reported
the association betwen HLA-DRB1*11 and
protection from IDDM in non-Caucasian
Table 2 - Distribution of HLA-DRB1 allele frequencies in
IDDM patients and normal individuals (controls).
The frequencies are represented as a percentage of each
allele in relation to the total number of alleles (2n) (when a
single DRB1 allele was found it was considered homozy-
gous and was counted twice). P values were obtained by
the chi-square test and corrected for the number of differ-
ent DRB1 alleles tested (Pc, multiplication of P by 13). RR,
Relative risk; NS, nonsignificant. *P<0.006 before correc-
tion.
DRB1* IDDM Controls RR Pc
(2n = 82) (2n = 198)
2n % 2n %
01 8 9.7 30 15.1 0.62 NS
15 5 6.1 19 9.6 0.61 NS
16 0 0.0 5 2.5 0.21 NS
03 27 32.9 21 10.6 4.13 <0.0002
04 23 28.0 15 7.6 4.76 <0.0002
11 4 4.9 37 18.7 0.22 *
12 0 0.0 4 2.0 0.26 NS
13 5 0.061 18 9.1 0.65 NS
14 0 0.0 9 4.5 0.12 NS
07 7 8.5 15 7.9 1.14 NS
08 1 1.2 6 3.0 0.38 NS
09 0 0.0 4 2.0 0.26 NS
10 0 0.0 9 4.5 0.12 NS
Table 1 - Distribution of HLA-DRB1 phenotype frequencies
in IDDM patients and normal individuals (controls).
The frequencies are represented as a percentage of pa-
tients with each allele. P values were obtained by the chi-
square test and corrected for the number of different DRB1
alleles tested (Pc, multiplication of P by 13). RR, Relative
risk; NS, nonsignificant. *P<0.03 before correction;
**P<0.02 before correction.
DRB1* IDDM Controls RR Pc
(N = 41) (N = 99)
N % N %
01 8 19.5 24 24.2 0.75 NS
15 5 12.2 14 14.1 0.85 NS
16 0 0.0 3 3.0 0.33 NS
03 20 48.8 18 18.2 4.27 <0.005
04 18 43.9 15 15.1 4.37 <0.008
11 3 7.3 26 26.3 0.22 * *
12 0 0.0 4 4.0 0.25 NS
13 5 12.2 14 14.1 0.85 NS
14 0 0.0 8 8.1 0.13 NS
07 5 12.2 12 12.1 1.00 NS
08 1 2.4 6 6.1 0.39 NS
09 0 0.0 3 3.0 0.33 NS
10 0 0.0 7 7.1 0.15 NS
03/04 6 14.6 3 3.0 5.44 *
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populations such as Blacks and North-Afri-
cans (17,18). In Caucasians, protection is
usually conferred by the DRB1*15-
DQA1*0102-DQB1*0602 haplotype (3).
However, DRB1*15 frequency was not de-
creased in our IDDM patients compared to
controls.
The HLA-DRB1* genes found in the
above Brazilian IDDM patients need to be
re-evaluated in conjunction with an analysis
of HLA-DQA1*, DQB1* haplotypes since
the latter represent the primary HLA genes
involved in susceptibility to the disease. Since
the combination of DQA1 and DQB1 genes
can vary among populations, detailed haplo-
type studies of different ethnic groups are
required in order to better define the nature
of the HLA-associated susceptibility and re-
sistance to IDDM.
References
1. Rossini AA, Greiner DL, Friedman HP &
Mordes JP (1993). Immunopathogenesis
of diabetes mellitus. Diabetes Reviews,
1: 43-75.
2. Bach JF (1994). Insulin-dependent diabe-
tes mellitus as an autoimmune disease.
Endocrine Reviews, 15: 516-542.
3. Thorsby E & Ronningen KS (1993). Par-
ticular HLA-DQ molecules play a domi-
nant role in determining susceptibility or
resistance to type I (insulin-dependent)
diabetes mellitus. Diabetologia, 36: 371-
377.
4. Todd JA, Bell JI & McDevitt HO (1987).
HLA-DQ beta gene contributes to sus-
ceptibility and resistance to insulin-de-
pendent diabetes mellitus. Nature, 329:
599-604.
5. Khalil I, D’Auriol L, Gobet M, Morin L,
Lepage G, Deschamps I, Park MS, Degos
L, Galibert F & Hors J (1990). A combina-
tion of HLA-DQß Asp57-negative and
HLA-DQa Arg52 confers susceptibility to
insulin-dependent diabetes mellitus. Jour-
nal of Clinical Investigation, 85: 1315-
1319.
6. Wolf E, Spencer KM & Cudworth AG
(1983). The genetic susceptibility of type-
I (insulin dependent) diabetes: analysis of
the HLA-DR association. Diabetologia, 24:
224-229.
7. Reitnauter PJ, Roseman JM, Barger BO,
Murphy CC, Kirk KA & Acton RT (1981).
HLA associations with insulin-dependent
diabetes mellitus in a sample of the
American black population. Tissue Anti-
gens, 17: 286-293.
8. Sakurami T, Ueno Y, Nagaoka K, Kuno S,
Iwaki Y & Park MS (1982). HLA-DR speci-
fications in Japanese with juvenile-onset
insulin-dependent diabetes mellitus. Dia-
betes, 31: 105-106.
9. Eizirik DL, Monteiro CMC, Voltarelli JC &
Foss MC (1987). Frequency of HLA anti-
gens in a Brazilian type I diabetic popula-
tion. Brazilian Journal of Medical and Bio-
logical Research, 20: 533-537.
10. Moraes ME, Fernandez-Viña M, Salatiel I,
Tsai S, Moraes JR & Stastny P (1993).
HLA class II DNA typing in two Brazilian
populations. Tissue Antigens, 41: 238-
242.
11. National Diabetes Data Group (1979).
Classification and diagnosis of diabetes
mellitus and other categories of glucose
intolerance. Diabetes, 28: 1039-1057.
12. Tillil H & Kobberling J (1987). Age-cor-
rected empirical genetic risks estimates
for first degree relatives of IDDM patients.
Diabetes, 36: 93-99.
13. Skyler JS & Marks JB (1993). Immune
intervention in type I diabetes mellitus.
Diabetes Reviews, 1: 15-42.
14. Ronningen KS, Spurkland A, Iwe T, Vartdal
F & Thorsby E (1991). Distribution of HLA-
DRB1, -DQA1 and -DQB1 alleles and
DQA1-DQB1 genotypes among Norwe-
gian patients with insulin-dependent dia-
betes mellitus. Tissue Antigens, 37: 105-
111.
15. Fernandez-Viña M, Ramirez LC, Raskin P
& Stastny P (1993). Genes for insulin-de-
pendent diabetes mellitus (IDDM) in the
major histocompatibility complex (MHC)
of African-Americans. Tissue Antigens,
41: 57-64.
16. Buyse I, Sandkuyl LA, Zamani
Ghabanbasani M, Gu XX, Boillon R, Bex
M, Dooms L, Emonds MP, Duhamel M,
Marynen P & Cassiman JJ (1994). Asso-
ciation of particular HLA class II alleles,
haplotypes and genotypes with suscepti-
bility to IDDM in the Belgian population.
Diabetologia, 37: 808-817.
17. Djoulah S, Khalil I, Beressi JP,
Benhamamouch S, Bessaoud K,
Deschamps I, Degos L & Hors J (1992).
The HLA-DRB1*0405 haplotype is most
strongly associated with IDDM in Algeri-
ans. European Journal of Immunogenet-
ics, 19: 381-389.
18. Garcia-Pacheco JM, Herbut B, Cutbush S,
Hitman GA, Zhonglin W, Magzoub M,
Bottazzo GF, Kiere C, West G, Mvere D,
Biro PA & Sachs JA (1992). Distribution of
HLA-DQA1, -DQB1 and -DRB1 alleles in
black IDDM patients and controls from
Zimbabwe. Tissue Antigens, 40: 145-149.
